Vertex Pharmaceuticals opened higher at $550.73, compared with its previous close of $540.00. In the last trading session, the stock traded between $549.89 and $563.80. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Vertex Pharmaceuticals is now worth
$ 301.15
giving a profit of
$ 201.15 (201.15%)
Note: Past profits do not guarantee future returns.
Rating from 25 Analysts
Today's Change
+$16.92 (+3.13%)
Day High
$563.80
Day Low
$549.89
Day Open
$550.73
Prev Close
$540.00
Volume
8,37,473
1W Return
4.03%
1M Return
5.74%
3M Return
15.25%
6M Return
31.58%
1Y Return
33.49%
Market Cap ($ Mn)
1,41,157
PE Ratio
31.55
PB Ratio
6.78
PEG Ratio
1.78
ROE
22.97%
ROCE
20.80%
EPS (TTM)
$4.34
1 Week
4.03%
1 Month
5.74%
3 Months
15.25%
6 Months
31.58%
9 Months
17.08%
Vertex Pharmaceuticals appoints Daniel Brennan to board of directors
Daniel Brennan appointed as independent director at Vertex Pharmaceuticals. Board size increased from 10 to 11 members following the appointment. Brennan previously served as CFO at Boston Scientific for over 25 years. He holds current directorships at Waters Corporation and Madrigal Pharmaceuticals.
9 days agoVertex to report Q3 2026 financial results on November 2
Vertex Pharmaceuticals will report Q3 2026 results on November 2, 2026. Conference call scheduled for 4:30 pm ET after market close. Webcast available via Vertex website; registration recommended 15 minutes early. Company holds approved therapies for cystic fibrosis and sickle cell disease.
22 days agoVertex reports positive Phase 2b data for kidney drug inaxaplin
Phase 2b AMPLIFIED trial showed 42.7% mean decrease in UACR for modest proteinuria cohort. Patients with type 2 diabetes saw 17.3% UACR drop and 25.4% UPCR decline. No serious adverse events linked to treatment; headache affected 7.3% of participants. Interim analysis for Phase 2/3 AMPLITUDE study expected in early 2027.
1mo agoVertex Pharmaceuticals delivers 14.69% annualized return over 20 years
Vertex Pharmaceuticals has achieved a 14.69% annualized return over 20 years, beating the market by 5.35%. With a current market cap of $129.65 billion, a $100 investment from two decades ago would now yield $1,569.05, demonstrating significant long-term value creation through compounding.
2mo agoBarclays raises Vertex Pharmaceuticals price target to $617
Barclays raises its price target on Vertex Pharmaceuticals to $617 from $615 while maintaining an Overweight rating. Analyst Eliana Merle’s move highlights sustained confidence in the biotech firm’s valuation. The modest increase suggests the stock is nearing fair value, yet the bank retains a bullish stance on its future performance.
2mo agoVertex Pharma Q2 EPS Meets Estimate, Sales Beat on Strong Momentum
Vertex Pharmaceuticals met Q2 EPS estimates at $4.73 and beat sales forecasts with $3.334 billion in revenue, driving a 12.45% year-over-year increase. The firm raised full-year 2026 guidance to $13.1B-$13.2B, citing strong performance in cystic fibrosis treatments and growing adoption of non-CF therapies like CASGEVY and JOURNAVX.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 | |
| $174.00 | -25.13% | $23,282.77M | 39.98 |
An investment of $100 made 5 years ago in Vertex Pharmaceuticals is now worth
$ 301.15
giving a profit of
$ 201.15 (201.15%)
Note: Past profits do not guarantee future returns.
